| 摘要 |
The invention is in the field of molecular diagnostics for cancer, in particular, for acute myeloid leukemia (AML). The invention provides methods for diagnosing AML patients with a favorable prognosis. We have found that not all AML patients carrying a CEBPA mutation may have a more favorable prognosis. We found that only the group with double mutations, i.e., biallelic mutations, have a particularly favorable prognosis. We also found a method that distinguishes mono-allelic CEBPA mutations from bi-allelic mutations. |
